Welcome to our dedicated page for Glucotrack SEC filings (Ticker: GCTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Glucotrack's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Glucotrack's regulatory disclosures and financial reporting.
Glucotrack, Inc. completed a strategic business combination in which Lōkahi Therapeutics becomes the operating and controlling business of the public company. Lōkahi securityholders received Glucotrack common and Series A preferred stock targeting a 90.0% fully diluted allocation to them, while pre‑merger Glucotrack holders are contractually protected to hold at least 10.0% of fully diluted equity through an Acquiror Stockholder Floor and potential Floor True‑Up Shares. Glucotrack’s legacy continuous blood glucose monitoring business is being transferred into a wholly owned subsidiary that will receive a staged $7,000,000 Subsidiary Contribution and retain all of Glucotrack’s cash and cash equivalents at Closing.
To finance the structure, Glucotrack issued approximately $4.45 million of senior secured convertible promissory notes with a 22% original issue discount, 8% annual interest, nine‑month maturity and Bridge Warrants providing 125% coverage of principal, secured by a first‑priority lien on substantially all assets other than the legacy operating subsidiary, and accompanied by extensive registration, repayment‑from‑proceeds and most‑favored‑nation rights. The company also entered into a three‑year equity line with White Lion Capital for up to $50,000,000 of common stock sales, in exchange for $1,000,000 of commitment shares and a warrant to purchase up to $10,000,000 of stock, plus liquidated damages if key registration and stockholder‑approval deadlines are missed. A new Series A Convertible Preferred Stock (1,000,000 shares, $40.30 Stated Value, 100:1 conversion ratio, no redemption and limited voting rights) will automatically convert into common stock after Acquiror Stockholder Approval and Nasdaq Trading Market Approval. Management changes include appointing Erik Emerson as chief executive officer, while Paul Goode becomes chief technical officer and leads the CBGM subsidiary. The company states that, after these transactions, it believes its stockholders’ equity exceeds Nasdaq’s $2.5 million continued‑listing requirement and is awaiting Nasdaq’s formal determination.
Glucotrack, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to consider election of five directors and several corporate actions. Key matters include: (1) approval of up to a 1-for-30 reverse stock split (management may implement any ratio up to that aggregate), (2) a warrant inducement/repricing proposal to permit repricing and issuance of inducement warrants to support exercise of certain private placement warrants, and (3) ratification of CBIZ CPAs P.C. as independent auditors. The proxy discloses 6,259,279 shares issued and outstanding and lists outstanding derivative instruments including 2,198,301 warrants and 16,499 option shares (all figures stated as of June 16, 2026). The reverse split is presented as a tool to address Nasdaq bid-price compliance and would be executed only if management elects to do so within one year; fractional shares would be rounded up.
Glucotrack, Inc. has received two Nasdaq deficiency notices that together threaten its continued listing on The Nasdaq Capital Market. The first relates to failure to meet the $1.00 per share minimum bid price requirement under Nasdaq Rule 5550(a)(2). The second, based on its Form 10-Q for the period ended March 31, 2026, states the company no longer meets the $2,500,000 minimum stockholders’ equity requirement under Listing Rule 5550(b)(1) and does not qualify under alternative standards.
The company plans to timely request a hearing before a Nasdaq Hearings Panel by May 18, 2026, which will temporarily stay delisting while it presents a plan to regain compliance. The filing cautions there is no assurance the appeal will succeed or that Glucotrack will be able to regain or maintain compliance with Nasdaq listing rules.
GLUCOTRACK, INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report 102,115 shares, representing 4.99% of common stock, with shared voting and dispositive power over those shares. The filing states the Master Fund has the right to receive dividends or sale proceeds for the reported securities.
Glucotrack, Inc. reported a larger share count and ongoing losses as it advances development of its implantable continuous blood glucose monitor. For the quarter ended March 31, 2026, the company recorded a net loss of $4,334 thousand, with research and development expenses of $2,132 thousand and general and administrative expenses of $2,071 thousand.
Cash and cash equivalents fell to $3,929 thousand from $7,383 thousand at year-end, and accumulated deficit reached $156,172 thousand. Management states these factors raise substantial doubt about its ability to continue as a going concern and expects to rely on additional equity or debt financings. Subsequent events include an IDE submission to the FDA for a U.S. clinical study, equity raises under an ELOC facility, debt-for-equity exchanges, and a Nasdaq staff determination to delist the stock for failing the $1.00 bid-price rule, which the company plans to appeal.
Glucotrack, Inc. reported first quarter 2026 results showing a narrower net loss while advancing its implantable continuous blood glucose monitor program. Net loss was $4.3 million for the quarter, compared with $6.8 million a year earlier, mainly due to a smaller non-cash impact from derivative liabilities.
Research and development expenses were $2.1 million and general and administrative expenses were $2.1 million, both up from the prior year as the company invested in product, manufacturing and corporate infrastructure. Cash and cash equivalents were $3.9 million as of March 31, 2026, down from $7.4 million at December 31, 2025.
The company submitted an Investigational Device Exemption application to the FDA for its fully implantable continuous blood glucose monitoring technology and is targeting a U.S. clinical trial launch in the second half of 2026. Management expects existing cash to fund operations into early third quarter 2026, supporting initiation of the planned U.S. human clinical trial shortly thereafter.
Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration to begin a U.S. clinical study of its fully implantable continuous blood glucose monitoring (CBGM) technology.
The system is designed as a long-term, blood-based continuous glucose monitor with no on-body wearable component and a sensor longevity of 3 years, aiming to provide real-time glucose data in a comfortable and discreet form. The IDE submission follows several years of engineering, preclinical evaluation, and iterative design work, and Glucotrack plans to proceed with the U.S. clinical study following FDA review and approval.
Glucotrack, Inc. entered into an Exchange Agreement to swap a $988,000 partitioned promissory note for 1,300,000 shares of its common stock. This is a debt-for-equity exchange with no cash paid by the investor, which reduces note principal while increasing the share count.
The issuance is subject to a 19.9% beneficial ownership limitation, so shares may be issued in tranches and any unexchanged portion of the note will remain outstanding. The company also furnished an updated investor presentation as an exhibit.
Glucotrack, Inc. reported new peer-reviewed data on its fully implantable continuous blood glucose monitoring (CBGM) system from an in-vivo ovine study. Thirty-four devices implanted in 17 adult sheep were followed for up to 240 days and achieved a weighted average Mean Absolute Relative Difference (MARD) of 6.8% across 79 intravenous glucose tolerance tests, indicating high accuracy, with no device-related adverse safety events observed.
The company noted that these preclinical results, together with prior first-in-human data showing a MARD of 7.7% with 99% data capture and no procedure- or device-related serious adverse events, help support its planned IDE submission to the FDA and continued clinical development of its long-life CBGM platform.